Posted by Michael Wonder on 04 Jul 2021
Galderma receives FDA approval for Restylane Contour for cheek augmentation and correction of midface contour deficiencies
29 June 2021 - Galderma's first and only product in the U.S. to use proprietary XpresHAn Technology for the cheeks.
Galderma announced today the U.S. FDA has approved Restylane Contour for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21.
Restylane Contour, a new hyaluronic acid dermal filler, is Galderma's first and only product in the U.S. formulated with XpresHAn Technology for the cheeks.
